744 / 1084
Summary
•
Two main types: intestinal and diffuse adenocarcinoma
•
Many (and rare) special types according to WHO
•
Heterogeneity of tumors is a big problem (morphology-based and
molecular-based; Her2/neu only focally expressed
•
Some progress in molecular subtyping
- MSI and EBV related: checkpoint inhibition effective?
Institute of Pathology | Alexander Quaas
Gastrointestinal Cancer Group Cologne (GCGC)
- rare other subtypes (BRCA, ATM, POLE)
•
>16 regional lymph nodes
•
Regression scores after neoadjuvant treatment (e.g. Becker
et.al)
•
Tumormicroenviroment